Chronic Spontaneous Urticaria Cyclosporine Treatment: Our Experience

Aim:Treatment of severe chronic autoimmune urticaria is difficult. In this study we aimed to investigate efficacy and safety of cyclosporine in patients with chronic urticaria.Material and Method:Twenty patients with chronic spontaneous urticaria whom detailed physical exami-nation were noted and we...

Full description

Saved in:
Bibliographic Details
Main Authors: Hilayda Karakök Güngör, Seçil Saral, Ayșenur Maden, Nihal Kundakçı, Beyza Doğanay Erdoğan, Bengü Nisa Akay
Format: Article
Language:English
Published: Galenos Publishing House 2016-08-01
Series:Ankara Üniversitesi Tıp Fakültesi Mecmuas
Subjects:
Online Access: http://ankaratipfakultesimecmuasi.net/archives/archive-detail/article-preview/chronic-spontaneous-urticaria-cyclosporine-treatme/18366
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim:Treatment of severe chronic autoimmune urticaria is difficult. In this study we aimed to investigate efficacy and safety of cyclosporine in patients with chronic urticaria.Material and Method:Twenty patients with chronic spontaneous urticaria whom detailed physical exami-nation were noted and were treated in our center between 2005 and 2013 were included in this study.Results:A total 20 patients were included in this study. Daily wheal number and number of angioedema at-tacks had been compared and significant reduce in both parameters were detected. Total duration of treat-ment was mean (min: 4, max: 144) 27,05 (±30,9507 SD, median 18) weeks. Daily cyclosporine dosages were (min: 0,54, max: 3,57), mean 2,2672 (±0,81441SD, median 2,1237). Mild hypertension was detected in two pati-ents under treatment and had been treated with anti hypertensive agents. Dyplopia was developed in 1 pati-ent. We observed elevated creatinine levels in 3 patients.Conclusion:A daily mean dosage of 2,2672 mg of cyclosporine is effective in treatment of chronic urticaria for a duration of 27 weeks. All patients must be followed up closely to monitore adverse events. Recurrence was seen in a mean 9 weeks after cessation of therapy.
ISSN:1307-5608
1307-5608